

REGISTER TODAY!

Phone: (Toll Free) 866-395-2805 • Fax: 212-201-6850
Email: section2006@medreviews.com • Website: www.medreviews.com

Event staff will be glad to assist you with any special needs (eg, physical, dietary).
Please contact Magda Sanchez prior to the event at 866-395-2805.

Issues and Controversies in the Management of Prostate Cancer With Hormonal Therapy

New England Section Satellite Symposium • Friday, September 29, 2006
Rhode Island Convention Center, Providence, Rhode Island

Name: _____

Specialty: _____

Mailing Address: _____

City: _____

State: _____

Zip: _____

Phone: _____

Fax: _____

Email Address: _____

Tear along perforations and mail.

1333 Broadway • Suite 400
New York, NY 10018

PRESORTED
FIRST-CLASS MAIL
U.S. POSTAGE PAID
HORSHAM, PA
PERMIT NO. 440

YOU ARE INVITED

ISSUES AND CONTROVERSIES

IN THE MANAGEMENT OF
PROSTATE CANCER WITH
HORMONAL THERAPY

SPONSORED BY:



Postgraduate Institute
for Medicine

SUPPORTED BY AN UNRESTRICTED
EDUCATIONAL GRANT FROM:



WATSON Urology
A Division of Watson Pharma, Inc.

COORDINATED BY:

MEDREVIEWS

SEPTEMBER 29, 2006

RHODE ISLAND CONVENTION CENTER | PROVIDENCE, RHODE ISLAND

Target Audience

This activity has been designed to meet the educational needs of urologists involved in the care of patients with BPH.

Statement of Need/Program Overview

Advances in prostate cancer prevention, detection, and treatments have given rise to a growing national awareness of the disease. This has resulted in a trend towards diagnosing cancers earlier in the course of the disease. Nevertheless, many men undergoing treatment for clinically localized prostate cancer will ultimately progress. Hormonal therapy represents first-line therapy for advanced prostate cancer. Luteinizing hormone-releasing hormone (LH-RH) agonists were developed in the late 1970s and were shown to decrease circulating levels of testosterone to castrate levels. LH-RH agonists quickly replaced DES and surgical castration as the preferred method for achieving androgen suppression in men with prostate cancer. A program reviewing recent advances in the use of LH-RH agonists for the treatment of prostate cancer should include discussion of treatment options, the role of maximum androgen blockade, optimal management of high-risk localized disease, management of the biochemical recurrence of that curative to prevent short- and long-term complications of hormonal therapy, and reimbursement issues.

Educational Objectives

After completing this activity, the participant should be better able to:

- Compare single-agent androgen suppression for advanced prostate cancer
- Discuss androgen blockade
- Identify the needs of the high-risk prostate cancer patient
- Review the effective management of biochemical recurrence in patients with prostate cancer
- Review adverse events associated with hormonal therapy for prostate cancer
- Discuss reimbursement issues with hormonal therapies for prostate cancer

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and MedReviews, LLC. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

NEW ENGLAND SECTION SATELLITE SYMPOSIUM

RHODE ISLAND CONVENTION CENTER PROVIDENCE, RHODE ISLAND

Friday, September 29, 2006

Registration and Full International Breakfast 6:00 AM - 6:45 AM

Scientific Program 6:45 AM - 7:50 AM

CONTRIBUTING FACULTY

Herbert Lepor, MD (Chair)

Professor and Martin Spatz Chairperson of
Urology and Professor of Pharmacology
New York University School of Medicine
New York, New York

Michael Brawer, MD

Director
Northwest Prostate Institute
Seattle, Washington

E. David Crawford, MD

Professor of Oncology/
Radiation Oncology
University of Colorado
Aurora, Colorado

M. Ray Painter, MD, FACS (Co-Chair)

Medical Director
Physician Reimbursement Systems
Denver, Colorado

Gerald Chodak, MD

Director
Midwest Prostate and Urology Health Center
Chicago, Illinois

David G. McLeod, MD

Residency Program Director and
Director, Urologic Oncology
Walter Reed Army Medical Center
Washington, DC

Mark Painter (Co-Chair)

President
Physician Reimbursement Systems
Denver, Colorado

To take part in this important educational offering, please complete the registration form and fax it to 212-201-6850. If you have any questions, feel free to contact Magda Sanchez at 866-395-2805 or via email at section2006@medreviews.com.

Upon receipt of your completed registration form, you will receive a confirmation letter with pertinent logistical information about this program.



NO POSTAGE
NECESSARY
IF MAILED
IN THE
UNITED STATES



BUSINESS REPLY MAIL
FIRST-CLASS MAIL PERMIT NO.7913 NEW YORK NY

POSTAGE WILL BE PAID BY ADDRESSEE

Section 2006
1333 BROADWAY STE 400
NEW YORK NY 10138-1044



Tear along perforations and mail.